# DSIP Dosage in Research: Doses, Routes, and Half-Life Studied > DSIP dosage in published research: the doses, routes, and species used across human and animal studies of the delta sleep-inducing peptide. Research context only, not a dosing guide. What doses and routes published studies actually used, in which species, with the half-life that shapes them all. A record of what was studied, not a recommendation. ## Read this first This page reports DSIP dosage the way the published studies recorded it, what amount was given, by what route, to which species, and nothing more. It is a research record, not a how-to, and it deliberately contains no human-use instructions. That matters here for a specific reason: DSIP is not an approved medicine, there is no validated human dosing standard, and its effects are unreliable and often absent. The doses below are written as 'studied at X in species Y' so the science is clear while staying firmly out of advice territory. One physical fact frames all of it, DSIP leaves the bloodstream within minutes, which is exactly why researchers gave it by injection and why a stable swallowed version does not exist. For what those few minutes mean, see the [DSIP half life](/half-life) page. ## DSIP dosage in human studies Across the human sleep and neuroendocrine literature, one figure dominates: 25 nmol/kg of body weight, given intravenously. That is the dose used in the chronic-insomnia sleep studies, where it improved disturbed sleep with the benefit appearing in the second hour after injection [2], and in the double-blind study that found modest improvements in sleep efficiency and latency versus placebo [18]. The same 25 nmol/kg intravenous dose was used in the human stress-axis study that found a selective reduction in plasma ACTH with no change in cortisol [4], and in an open pilot in alcohol and opiate withdrawal [19]. The consistency of that single dose across the human work is striking; what is missing is any modern controlled trial that would turn a research figure into a validated standard. There is none. ## DSIP peptide dosage in animal models Animal DSIP peptide dosage spans a wide range because the studies asked different questions. In cats, subcutaneous DSIP at 120 nmol/kg increased slow-wave sleep without suppressing REM [7]. In the mouse longevity work, the Deltaran preparation was given at roughly 100 micrograms/kg (about 2.5 micrograms per mouse) subcutaneously, in monthly five-day courses, the schedule tied to the lifespan and tumor-incidence findings [5]. The 2024 fusion-peptide insomnia study used 100 nM solutions over five consecutive days in a chemically induced insomnia model [6]. Routes across the animal literature include intracerebroventricular (directly into the brain), subcutaneous, intranasal, and in-vitro perfusion. The breadth is the point: no single dose, route, or species generalizes cleanly to another, which is one more reason a human dosing recommendation cannot be drawn from this record. ## DSIP peptide nasal spray: what the research does and doesn't say Searches for a DSIP peptide nasal spray are common, so here is the honest state of it. Intranasal delivery has been used in animal research, an intranasal route appears in the rat neuroprotection literature, on the logic that the nasal passage can offer the brain a shorter path. But there is no approved DSIP nasal-spray product, no validated human intranasal dosing, and no controlled human trial of an intranasal formulation [3]. Any nasal product sold online is an unregulated research preparation with no pharmaceutical standard for concentration, purity, or sterility. The interest is understandable given DSIP's very short half-life, but the evidence base for a nasal spray specifically is not there. ## Stability and why route matters so much DSIP is a short peptide subject to rapid enzymatic degradation in plasma, which is why nearly every study used injection or direct delivery rather than an oral route, and why so much modern interest is in modified, more stable analogs [17]. The naturally phosphorylated form DSIP-P and other synthetic analogs are reported to be more stable or potent in some assays, and the 2024 engineered fusion peptide was explicitly designed to survive longer and cross into the brain, outperforming native DSIP [6]. Lyophilized (freeze-dried) research peptide is typically reconstituted in sterile or bacteriostatic water for laboratory use, with no pharmaceutical-grade product or stability standard in existence. Read alongside the missing human pharmacokinetics, the takeaway is that delivery and stability, not dose alone, are the unsolved engineering problems. --- An evidence-appraisal digest of the delta sleep-inducing peptide record, read like an instrument panel — the 1977 delta-wave finding and the few small human results logged where the studies confirm them, and the dials that never gave a reading (no receptor, no modern trial, no validated human half-life) left openly blank; no clinic behind the panel and nothing here dosed, supplied, prescribed, or sold.